-
KARD share price: currently unavailable. Sorry, we currently don't have enough data to create an insight.
-
Price change
The price of KARD shares has increased $0.35 since the market last closed. This is a 1.71% rise.
-
Closed at $20.82.
The stock has remained unchanged in after-hours trading.
Key terms
About KARD
Kardigan, Inc. is a clinical-stage precision therapeutics company, which engages in developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. It combines clinical-stage drug programs with artificial intelligence, real-world patient data, and analytics through its “Cardiac Intelligence” platform to accelerate research and improve treatment outcomes. The company was founded by Tassos E. Gianakakos, Jay Edelberg, Bob McDowell, Leslie Leinwand, and Elizabeth McNally in August 2023 and is headquartered in Princeton, NJ.
-
Market cap: $1.94B
A market capitalization between $300 million and $2 billion places KARD in the small capitalization category.
Key terms
Smart score
Latest KARD news
No recent press releases are available for KARD
KARD Financials
-
KARD total_revenue: currently unavailable. Sorry, we currently don't have enough data to create an insight.
-
KARD net income: currently unavailable. Sorry, we currently don't have enough data to create an insight.
-
KARD earnings per share: currently unavailable. Sorry, we currently don't have enough data to create an insight.
Key terms
KARD Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
KARD Competitors
-
How competitors are chosen
KARD's competitors are included in the Health Technology sector and Biotechnology group
-
Market cap: $1.94B
A market capitalization between $300 million and $2 billion places KARD in the small capitalization category.
